Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the…
The EU MDR 2017/745 is a rigorous regulatory certification program for medical devices intended to support innovation while maintaining safety. The process for THERAKOS to achieve this new CE certificate involved a quality management system audit of the Dublin site, a technical review, a microbiological review, and a thorough clinical assessment. The EU MDR 2017/745 is a rigorous regulatory certification program for medical devices intended to support innovation while maintaining safety...
PR Newswire
03/09/2024
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the…
The EU MDR 2017/745 is a rigorous regulatory certification program for medical devices intended to support innovation while maintaining safety. The process for THERAKOS to achieve this new CE certificate involved a quality management system audit of the Dublin site, a technical review, a microbiological review, and a thorough clinical assessment. The EU MDR 2017/745 is a rigorous regulatory certification program for medical devices intended to support innovation while maintaining safety...
PR Newswire
03/09/2024
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference…
For more information, please contact:Orexo AB (publ.)Lena Wange, IR & Communications Director+46 18 780 88
[email protected]
For more information, please contact: Orexo AB (publ.) Lena Wange, IR & Communications Director +46 18 780 88
[email protected]
About Orexo Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo...
PR Newswire
03/09/2024
AMSilk joins World Economic Forum's Global Innovators Community
Ulrich Scherbel, Chief Executive Officer of AMSilk, commented: "Being invited to join the World Economic Forum's Global Innovators Community stands as testament to our status as a global leader in advanced biomaterials. We look forward to continuing to demonstrate our commitment to innovation, industrial biotechnology and the advancement of the bioeconomy by contributing to the Forum's important work and initiatives." Ulrich Scherbel, Chief Executive Officer of AMSilk, commented…
PR Newswire
03/09/2024
QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be…
BEIJING, Sept. 3, 2024 /PRNewswire/ -- Beijing QL Biopharmaceutical Co., Ltd. ("QL Biopharm"), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces that an abstract on its lead drug candidate ZT002 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain on Thursday 12 September 2024. BEIJING,Sept. 3, 2024/PRNewswire/ -- Beijing QL…
PR Newswire
03/09/2024
Aidoc Launches Seven New AI Solutions to Tackle Europe's Healthcare Challenges
The new algorithms, which have now all achieved medical device CE-marking under MDR, include four solutions for notifying and triaging urgent pathologies: vessel occlusion, aortic dissection, vertebral compression fractures and malpositioned endotracheal tube. Alongside these, there are three new quantification solutions that provide standardised quantitative assessments of cardiovascular and neurological conditions: midline shift, coronary artery calcification and abdominal aortic measurement…
PR Newswire
03/09/2024
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company's next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline Appointment follows achievement of three key milestones for Amphista in 2024 which demonstrated: in vivo efficacy, ability to target and degrade proteins in the CNS and novel mechanism of action for the degradation of proteins ...
Nasdaq GlobeNewswire
03/09/2024
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology…
INGELHEIM, Germany, September 03, 2024– Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life expectancy for pets increases, so does the need for effective treatment of debilitating...
Nasdaq GlobeNewswire
03/09/2024
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept.03, 2024(GLOBE NEWSWIRE) -- The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("...
Nasdaq GlobeNewswire
03/09/2024
Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular…
The Cristofanilli lab will analyze the isolated plasma samples for cell-free DNA (cfDNA), while Tethis scientists will examine the isolated cells for circulating tumor cells (CTCs). The scientists will combine their results and examine them in the light of how the people being treated actually fared, and will publish the results together. The results could guide individualized treatment for people with early-stage breast cancer in the future. The Cristofanilli lab will analyze the isolated...
PR Newswire
03/09/2024
New European Customer Orders Nexstim NBS System 5
Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new European customer through a distributor.The Nexstim Navigated Brain Stimulation (NBS) System 5 is the only FDA-cleared and CE-marked navigated TMS (Transcranial Magnetic Stimulation) system for pre-operative mapping of the motor and speech cortices of the brain.Mikko...
Nasdaq GlobeNewswire
03/09/2024
CMR Surgical Strengthens Senior Team
CMR Surgical Strengthens Senior Team Markus Bauman, seasoned senior executive has been appointed Chief Legal & Business Affairs Officer and will join CMR's executive leadership teamMichelle Paknad, appointed Senior Vice President, Global Business Development, brings a wealth of commercial experience in the soft-tissue surgical robotics industry Cambridge, UK – 3 September 2024, 07:00 (BST).CMR Surgical (CMR or 'the Company'), the global surgical robotics business, today...
Nasdaq GlobeNewswire
03/09/2024
ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant…
Grant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI) The ongoing early feasibility clinical study is also supported by the European Innovation Council under theReverse Paralysisproject. The first study participant was implanted with the investigational ARC-BCI System in August 2023. The Reeve Foundation's $1.1 million grant to study...
Nasdaq GlobeNewswire
03/09/2024
BinSina Pharmacy invites the UAE to celebrate 59 years of well-being together
Founded in 1965, BinSina Pharmacy has been an integral part of the UAE's healthcare landscape for nearly six decades, bringing healthy, beautiful living to people in the UAE and beyond. Over the years, the renowned pharmacy chain has grown to encompass a network of over 150 stores plus an expansive e-commerce presence, offering a comprehensive range of health and beauty products. Founded in 1965, BinSina Pharmacy has been an integral part of the UAE's healthcare landscape for nearly six...
PR Newswire
03/09/2024
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme…
VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populationsSignificant anamnestic antibody response observed across all six serotypes, consistent with previous resultsFavorable safety profile of VLA15 observed in all age groups and for all vaccinationsSaint-Herblain (France) and New York, NY, September 3, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced...
Nasdaq GlobeNewswire
03/09/2024
CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive…
Clermont-Ferrand (France), 3 September 2024 (06:45 CET). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the appointment of Tommy Maussin as its Chief Marketing Officer, effective 2 September 2024. His mission involves developing and overseeing CARBIOS' global marketing and sales activities with brands across various industries, including packaging,...
Nasdaq GlobeNewswire
03/09/2024
NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of…
Key Takeaways from the NRG Fusion Market Report Key Takeaways from the NRG Fusion Market Report Discover which therapies are expected to grab the NRG fusion market share @NRG Fusion Market Report NRG Fusion Market Dynamics NRG fusions have been found inmore than 10types of solid tumors, suggesting they are a promising target for a broad, tumor-agnostic therapeutic approach. Increasing awareness and research in this area make it an appealing opportunity for major industry...
PR Newswire
03/09/2024
Global Cancer Monoclonal Antibodies Market to Cross ~USD 157 Billion Mark by…
Key Takeaways from the Cancer Monoclonal Antibodies Market Report Key Takeaways from the Cancer Monoclonal Antibodies Market Report To read more about the latest highlights related to the cancer monoclonal antibodies market, get a snapshot of the key highlights entailed in the Global Cancer Monoclonal Antibodies Market Report Cancer Monoclonal Antibodies Overview Monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering highly targeted therapies that...
PR Newswire
02/09/2024
Roche's PIASKY Approval for Paroxysmal Nocturnal Hemoglobinuria Treatment Will…
In 2023, the Paroxysmal Nocturnal Hemoglobinuria diagnosed prevalent cases were ~12,000 cases in the 7MM, which might reach ~13,000 cases by 2034. In the 7MM, the highest number of paroxysmal nocturnal hemoglobinuria diagnosed prevalent cases were observed in the US. In 2023, the Paroxysmal Nocturnal Hemoglobinuria diagnosed prevalent cases were~12,000cases in the 7MM, which might reach~13,000cases by 2034. In the 7MM, the highest number of paroxysmal nocturnal hemoglobinuria diagnosed...
PR Newswire
02/09/2024
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch…
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company's Genio® device is complete, U.S. approval on track for the end of 2024U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised Nyxoah – NASDAQ Closing Bell Ceremony 29 août 2024Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA...
Nasdaq GlobeNewswire
02/09/2024
Trading by management and close relations of management
Please read the full announcement in PDF Attachment 2024_31_Trading_By_Management
Nasdaq GlobeNewswire
02/09/2024
Trading by management and close relations of management
Please read the full announcement in PDF Attachment 2024_30_Trading_By_Management
Nasdaq GlobeNewswire
02/09/2024
Amended terms of Idorsia's 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the amended terms of Idorsia's outstanding convertible bonds, originally maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds) have become effective.The cut-off date in respect of the consent fee is today, which means that bondholders holding the Bonds on – or who have...
Nasdaq GlobeNewswire
02/09/2024
Non-invasive Prenatal Testing (NIPT) Market worth $14.1 billion by 2029 driven…
Browse in-depth TOC on "Non-invasive Prenatal Testing (NIPT) Market" Browse in-depth TOC on "Non-invasive Prenatal Testing (NIPT) Market" 506 - Tables 63 - Figures 370 - Pages Illumina, Inc.: Pioneering Genetic Analysis Solutions Illumina, Inc. (US) leads the molecular diagnostics space with integrated systems for analyzing genetic variation and biological functions. The company offers a comprehensive range of products, including integrated systems, consumables, and...
PR Newswire
02/09/2024
Altri Comunicati
